Modality
Cell Therapy
MOA
FGFRi
Target
WEE1
Pathway
PI3K/AKT
CTCLOCDLN
Development Pipeline
Preclinical
May 2021
→ Mar 2030
PreclinicalCurrent
NCT03638912
2,888 pts·LN
2021-07→2030-03·Recruiting
NCT04977889
2,260 pts·OCD
2021-05→2025-11·Terminated
5,148 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-065mo agoInterim· OCD
2030-03-184.0y awayInterim· LN
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Preclinical
Termina…
Preclinical
Recruit…
Catalysts
Interim
2025-11-06 · 5mo ago
OCD
Interim
2030-03-18 · 4.0y away
LN
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03638912 | Preclinical | LN | Recruiting | 2888 | NT-proBNP |
| NCT04977889 | Preclinical | OCD | Terminated | 2260 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| Elrainavolisib | Roivant Sciences | Preclinical | Nectin-4 | |
| Bemavorutinib | Acadia Pharma | Phase 1/2 | WEE1 |